Earnings Call Summary | Zimmer Biomet Holdings(ZBH.US) Q1 2024 Earnings Conference
Earnings Call Summary | Zimmer Biomet Holdings(ZBH.US) Q1 2024 Earnings Conference
The following is a summary of the Zimmer Biomet Holdings, Inc. (ZBH) Q1 2024 Earnings Call Transcript:
以下是Zimmer Biomet Holdings, Inc.（ZBH）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Zimmer Biomet reported a Q1 2024 revenue growth of 4.4%, exceeding company expectations due to strong markets and effective execution.
Q1 2024 net sales were $1.889 billion, a reported increase of 3.2% or 4.4% excluding foreign currency's impact.
Gross margin was increased due to sales growth, accelerated savings from the restructuring program and a lower share count.
Despite a 200 basis point increase in the effective tax rate, Zimmer expanded its adjusted margin and grew its adjusted earnings.
Operating cash inflows and free cash inflow during Q1 2024 were reported as $228 million and $91 million, respectively.
The company's GAAP diluted earnings per share stood at $0.84 while adjusted diluted earnings per share were reported at $1.94.
Zimmer Biomet報告稱，由於強勁的市場和有效的執行，2024年第一季度收入增長4.4％，超出了公司的預期。
2024年第一季度的淨銷售額爲18.89億美元，據報告增長3.2％，增長4.4％，不包括外幣的影響。
毛利率的增加是由於銷售增長、重組計劃帶來的節約加速以及股票數量的減少。
儘管有效稅率提高了200個點子，但Zimmer還是擴大了調整後的利潤率並增加了調整後的收益。
據報告，2024年第一季度的運營現金流入和自由現金流入分別爲2.28億美元和9,100萬美元。
該公司的GAAP攤薄後每股收益爲0.84美元，而調整後的攤薄後每股收益爲1.94美元。
Business Progress:
業務進展：
Zimmer experienced high patient demand, driven by demographic shifts affecting their end markets.
Globally, ROSA technology and Persona Knee products' adoption was a primary driver of results.
Revenue growth is expected to accelerate in H2 2024 due to new product releases including Persona OsseoTi, HAMMR surgical impactor, and ROSA Shoulder.
Zimmer is entering the direct anterior hip category with their triple taper hip stem, Z1, increasing competition in that market.
Strategic priorities focusing on people and culture, operational excellence, and diverse innovation were upheld for long-term success.
The company improved their inventory management programs significantly and promised a notable improvement in Days on Hand (DOH) in 2024.
Zimmer aims for 5% to 6% revenue growth and EPS growth between $8 to $8.15 in 2024, with expected free cash flow generation between $1.0 to $1.1 billion.
The company leans towards smaller, accretive tuck-in acquisitions of up to $2 billion, expecting these to be EPS neutral within two years and aims to regain their leading position in Hip surgery with their latest product innovations.
Zimmer Biomet persisted in investing in areas of potential high-growth such as robotic penetration and cementless adoptions, aiming for 60% penetration.
受影響終端市場的人口結構變化的推動，Zimmer 的患者需求居高不下。
在全球範圍內，ROSA技術和Persona Knee產品的採用是業績的主要驅動力。
由於包括Persona OsseoTi、HAMMR手術衝擊器和ROSA Shoulder在內的新產品的發佈，預計收入將在2024年下半年加速。
Zimmer憑藉其三錐度髖關節杆Z1進入直前髖關節類別，這加劇了該市場的競爭。
堅持以人員和文化、卓越運營和多元創新爲重點的戰略重點，以取得長期成功。
該公司顯著改善了庫存管理計劃，並承諾在2024年顯著改善Days on Hand（DOH）。
齊默的目標是在2024年實現5％至6％的收入增長，每股收益增長8至8.15美元，預計產生的自由現金流在10億至11億美元之間。
該公司傾向於進行規模較小、增值高達20億美元的收購，預計這些收購將在兩年內實現每股收益中和，並計劃通過最新的產品創新重新獲得其在髖關節外科領域的領先地位。
Zimmer Biomet堅持投資於潛在的高增長領域，例如機器人滲透率和無水泥採用率，目標是達到60％的滲透率。
More details: Zimmer Biomet Holdings IR
更多詳情： Zimmer Biomet 控股投資者關係
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。